GLA
GSK icon

Good Life Advisors’s GSK GSK Stock Holding History

Good Life Advisors’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$234K Sell
6,102
-344
-5% -$13.1K 0.01% 455
2025
Q1 		$250K Buy
+6,446
New +$236K 0.02% 424
2024
Q4 		– Sell
-14,486
Closed -$592K – 535
2024
Q3 		$592K Buy
14,486
+6,864
+90% +$281K 0.04% 306
2024
Q2 		$293K Buy
7,622
+681
+10% +$28.6K 0.02% 362
2024
Q1 		$298K Sell
6,941
-3
-0% -$124 0.03% 351
2023
Q4 		$257K Buy
6,944
+16
+0.2% +$574 0.03% 359
2023
Q3 		$251K Buy
+6,928
New +$246K 0.03% 347
2022
Q3 		– Sell
-3,788
Closed -$206K – 354
2022
Q2 		$206K Sell
3,788
-1,094
-22% -$60.4K 0.03% 319
2022
Q1 		$266K Buy
4,882
+152
+3% +$8.26K 0.03% 313
2021
Q4 		$261K Sell
4,730
-106
-2% -$5.51K 0.03% 309
2021
Q3 		$231K Buy
+4,836
New +$243K 0.03% 311
2021
Q2 		– Sell
-4,531
Closed -$202K – 330
2021
Q1 		$202K Buy
4,531
+19
+0.4% +$862 0.04% 299
2020
Q4 		$205K Sell
4,512
-225
-5% -$10.3K 0.05% 252
2020
Q3 		$223K Sell
4,737
-726
-13% -$36.4K 0.06% 208
2020
Q2 		$277K Buy
5,463
+83
+2% +$4.26K 0.08% 177
2020
Q1 		$255K Sell
5,380
-109
-2% -$5.81K 0.09% 171
2019
Q4 		$323K Sell
5,489
-165
-3% -$9.18K 0.09% 178
2019
Q3 		$303K Sell
5,654
-29
-0.5% -$1.49K 0.09% 177
2019
Q2 		$283K Buy
5,683
+1,443
+34% +$72.4K 0.08% 178
2019
Q1 		$223K Buy
+4,240
New +$212K 0.07% 212
2017
Q2 		– Sell
-3,823
Closed -$200K – 210
2017
Q1 		$200K Buy
+3,823
New +$194K 0.1% 185

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return

Good Life Advisors's GSK Position: Q2 2025 in Review

Good Life Advisors reduced its GSK (GSK) stake by 5.3% in Q2 2025, selling an estimated $13.1K and leaving 6,102 shares worth $234K. The position accounts for 0.01% of the portfolio, ranked #455.

Good Life Advisors first reported a position in GSK in Q1 2017 and has held it in 21 quarters since. The position peaked at $592K in Q3 2024. 891 funds tracked by Wall St. Rank hold GSK as of Q2 2025.

  • Good Life Advisors held 6,102 shares of GSK worth $234K as of Q2 2025.
  • Good Life Advisors sold 344 GSK shares in Q2 2025, an estimated $13.1K.
  • GSK made up 0.01% of Good Life Advisors's portfolio in Q2 2025, its #455 holding.
  • Good Life Advisors first reported a position in GSK in Q1 2017 and has held it in 21 quarters since.
  • Good Life Advisors's GSK position peaked at $592K in Q3 2024.
  • 891 funds tracked by Wall St. Rank held GSK as of Q2 2025.

Based on Good Life Advisors's 13F filing for Q2 2025, filed 8 Aug 2025.